心血管

订阅

MedSci主页 / 所有栏目 / 心血管

真实世界研究：达比加群酯与利伐沙班相比主要出血风险相似

2018-01-29 MedSci MedSci原创

达比加群酯真实世界研究出血风险
关注

Pradaxa (达比加群酯) 是一种全新的抗凝血制剂，能够直接抑制凝血酶，被誉为六十年来最佳的防治中风药物。该药物的母公司，勃林格殷格翰近日公布了一项回顾性、观察性真实世界研究结果，该研究评估了通过美国国防部军事卫生系统治疗的非瓣膜性心房颤动（NVAF）患者使用新型口服抗凝剂（NOACs）的安全性和有效性。该研究探究了经达比加群酯治疗的NVAF患者与使用利伐沙班或阿哌沙班治疗的患者的主要出血风险

Pradaxa (达比加群酯) 是一种全新的抗凝血制剂，能够直接抑制凝血酶，被誉为六十年来最佳的防治中风药物。该药物的母公司，勃林格殷格翰近日公布了一项回顾性、观察性真实世界研究结果，该研究评估了通过美国国防部军事卫生系统治疗的非瓣膜性心房颤动（NVAF）患者使用新型口服抗凝剂（NOACs）的安全性和有效性。该研究探究了经达比加群酯治疗的NVAF患者与使用利伐沙班或阿哌沙班治疗的患者的主要出血风险。研究结果公布于2018年国际中风会议。

乔治城医学院助理教授Todd C. Villines博士说：“随着270万美国房颤患者越来越多地接受NOACs治疗，像这样的真实世界研究来分析比较它们的有效性和安全性是非常重要的。作为研究人员和治疗医师，我希望这一大规模的实践调查能够提供更多关于包括Pradaxa在内的NOAC治疗方面的信息。”

达比加群酯的使用说明书上并不包括将产品与其他NOAC疗法进行比较的数据，也没有提供NOAC疗法药物之间头对头的临床试验结果。因此该项真实世界研究系统性地论证了达比加群酯的安全性和有效性。

原始出处：

http://www.firstwordpharma.com/node/1539208?tsid=4#axzz55NkMXJoh

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797664, encodeId=0c6d1e97664a4, content=<a href='/topic/show?id=1d492326842' target=_blank style='color:#2F92EE;'>#主要出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23268, encryptionId=1d492326842, topicName=主要出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Dec 31 07:11:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284610, encodeId=b4732846108b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 03 01:30:57 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283912, encodeId=01ce283912ca, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jan 31 19:59:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295188, encodeId=c31612951883b, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Jan 31 02:11:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283513, encodeId=3c8828351348, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4b12216028, createdName=120e71dcm28暂无昵称, createdTime=Tue Jan 30 13:05:05 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-12-31 zhangyxzsh

    #主要出血#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1797664, encodeId=0c6d1e97664a4, content=<a href='/topic/show?id=1d492326842' target=_blank style='color:#2F92EE;'>#主要出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23268, encryptionId=1d492326842, topicName=主要出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Dec 31 07:11:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284610, encodeId=b4732846108b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 03 01:30:57 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283912, encodeId=01ce283912ca, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jan 31 19:59:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295188, encodeId=c31612951883b, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Jan 31 02:11:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283513, encodeId=3c8828351348, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4b12216028, createdName=120e71dcm28暂无昵称, createdTime=Tue Jan 30 13:05:05 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-02-03 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1797664, encodeId=0c6d1e97664a4, content=<a href='/topic/show?id=1d492326842' target=_blank style='color:#2F92EE;'>#主要出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23268, encryptionId=1d492326842, topicName=主要出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Dec 31 07:11:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284610, encodeId=b4732846108b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 03 01:30:57 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283912, encodeId=01ce283912ca, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jan 31 19:59:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295188, encodeId=c31612951883b, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Jan 31 02:11:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283513, encodeId=3c8828351348, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4b12216028, createdName=120e71dcm28暂无昵称, createdTime=Tue Jan 30 13:05:05 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-01-31 虈亣靌

    谢谢分享学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1797664, encodeId=0c6d1e97664a4, content=<a href='/topic/show?id=1d492326842' target=_blank style='color:#2F92EE;'>#主要出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23268, encryptionId=1d492326842, topicName=主要出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Dec 31 07:11:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284610, encodeId=b4732846108b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 03 01:30:57 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283912, encodeId=01ce283912ca, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jan 31 19:59:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295188, encodeId=c31612951883b, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Jan 31 02:11:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283513, encodeId=3c8828351348, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4b12216028, createdName=120e71dcm28暂无昵称, createdTime=Tue Jan 30 13:05:05 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-01-31 chenshujs

    #真实世界#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1797664, encodeId=0c6d1e97664a4, content=<a href='/topic/show?id=1d492326842' target=_blank style='color:#2F92EE;'>#主要出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23268, encryptionId=1d492326842, topicName=主要出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Dec 31 07:11:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284610, encodeId=b4732846108b, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Feb 03 01:30:57 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283912, encodeId=01ce283912ca, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Jan 31 19:59:15 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295188, encodeId=c31612951883b, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Jan 31 02:11:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283513, encodeId=3c8828351348, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4b12216028, createdName=120e71dcm28暂无昵称, createdTime=Tue Jan 30 13:05:05 CST 2018, time=2018-01-30, status=1, ipAttribution=)]
    2018-01-30 120e71dcm28暂无昵称

    学习了

    0

相关资讯

疗效相当，更少出血风险，达比加群酯新适应证在中国获批

日前，国家食品药品监督管理总局（CFDA）已批准新型口服抗凝药物泰毕全（通用名：达比加群酯）新适应证：治疗急性深静脉血栓形成（DVT）和/或肺栓塞（PE）以及预防相关死亡；预防复发性DVT和/或PE以及相关死亡。

Stroke：达比加群酯致出血性卒中的发生率低于华法林

亚洲人群的颅内出血发生率高于非亚洲人群，尤其是在那些进行华法林治疗的患者。亚洲和非亚洲人群中使用达比加群酯与华法林对卒中及出血发生率的影响尚不清楚。为此，一项国际合作研究对此进行探讨，我国阜外心血管医院的朱俊教授等人参与了该项目，研究成果在线发表在2013年6月6日的Stroke杂志上。研究结果显示：在相似的血压、年龄和国际标准化比值（INR）下，亚洲人群使用华法林的出血性卒中发生率高于非亚洲人群

ESC全新重磅：房颤患者支架置入术后使用达比加群酯双联治疗大出血发生率显著低于华法林三联治疗

RE-DUAL PCI显示，与华法林三联治疗相比，达比加群酯（泰毕全）双联治疗大幅度降低出血并发症 RE-DUAL PCI中使用的两种剂量的达比加群酯均已获批用于房颤卒中预防 研究结果作为“最新突破”在2017欧洲心脏病学会年会（ESC）发布，并同时发表在《新英格兰杂志》

J Thromb Haemost：达比加群酯：儿童VTE患者的新选择

儿童静脉血栓（VTE）的发病率为每10000名儿童中约有0.07~0.14例，近年来有所增加。2017年11月，发表在《J Thromb Haemost》的一项由加拿大、瑞士、澳大利亚、美国等国科学家进行的研究，考察了达比加群酯（DE）治疗儿童VTE的药动学、安全性及耐受性。

达比加群酯在欧洲获批用于治疗DVT和PE

6月6日，欧盟委员会批准勃林格殷格翰达比加群酯用于治疗深静脉血栓形成(DVT)和肺栓塞(PE)，这使得这款抗凝血剂产品与其竞争对手站在了同一起跑线上。 达比加群酯已被批准用于治疗和预防成人患者DVT和PE的复发，使其可以与拜耳/强生的利伐沙班进行一对一的竞争，利伐沙班已被批准用于这一适应症，此外，达比加群酯已走在了辉瑞/百时美施贵宝阿哌沙班的前头，阿哌沙班的这一适应症目前正在欧洲